Compare Vaxcyte Inc. Common Stock (PCVX) vs VanEck Vietnam ETF (VNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vaxcyte Inc. Common Stock vs VanEck Vietnam ETF — how do they compare? Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B), while VanEck Vietnam ETF trades at $16.38 (market cap $465.30M). The key difference: Vaxcyte Inc. Common Stock is far larger — about 22.6× VanEck Vietnam ETF's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, VanEck Vietnam ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and VanEck Vietnam ETF for 52 Days on average.
| PCVX | VNM | |
|---|---|---|
Market Cap | $10.51B | $465.30M |
Volume | 2,644,694 | 633,123 |
Sector | Health | Sector/Thematic |
52-Week High | $73.82 | $19.80 |
52-Week Low | $40.32 | $16.34 |
Typical Hold Time | 0 Days | 52 Days |
Enterprise Value | $9.14B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VNM stock trades at $16.53, down 0.3% with a bearish technical signal from moving averages. The ETF faces sector concentration risks in real estate and financials while trading at fair valuation. Recent news highlights Vietnam's potential US trade deal progress, though the fund has underperformed despite country growth prospects.
Near-term outlook remains cautious due to technical weakness and sector headwinds. Long-term exposure to Vietnam's growth offers potential, but investors face volatility from interest rate sensitivity and concentrated sector risks. The bearish technical setup suggests continued pressure on current price levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →About VanEck Vietnam ETF
VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →
